Literature DB >> 25052484

Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis.

Carl N Wivagg1, Roby P Bhattacharyya2, Deborah T Hung3.   

Abstract

β-Lactams are one of the most useful classes of antibiotics against many common bacterial pathogens. One exception is Mycobacterium tuberculosis. However, with increasing incidence of multidrug-resistant tuberculosis and a need for new agents to treat it, the use of β-lactams, specifically the combination of carbapenem and clavulanate, is now being revisited. With this attention, comes the need to better understand both the mechanisms of action of β-lactams against M. tuberculosis as well as possible mechanisms of resistance, within the context of what is known about the β-lactam action in other bacteria. M. tuberculosis has two major mechanisms of intrinsic resistance: a highly active β-lactamase and a poorly permeable outer membrane. Within the cell wall, β-lactams bind several enzymes with differing peptidoglycan-synthetic and -lytic functions. The inhibition of these enzymes may lead to cell death through several mechanisms, involving disruption of the balance of synthetic and lethal activities. Currently, all known means of resistance to the β-lactams rely on diminishing the proportion of peptidoglycan-synthetic proteins bound and inhibited by β-lactams, through either exclusion or destruction of the antibiotic, or through replacement or supplementation of target enzymes. In this review, we discuss possible mechanisms for β-lactam activity in M. tuberculosis and the means by which it may acquire resistance, within the context of what is known in other bacterial species.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25052484     DOI: 10.1038/ja.2014.94

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  22 in total

1.  Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Authors:  Shiqi Xiao; Haidan Guo; Warren S Weiner; Clinton Maddox; Chunhong Mao; Hendra Gunosewoyo; Shaaretha Pelly; E Lucile White; Lynn Rasmussen; Frank J Schoenen; Jeffrey Aubé; William R Bishai; Shichun Lun
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.

Authors:  Pankaj Kumar; Amit Kaushik; Drew T Bell; Varsha Chauhan; Fangfang Xia; Rick L Stevens; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 3.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

Authors:  Daniel T Hoagland; Jiuyu Liu; Robin B Lee; Richard E Lee
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

4.  Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility.

Authors:  Karen J Kieser; Catherine Baranowski; Michael C Chao; Jarukit E Long; Christopher M Sassetti; Matthew K Waldor; James C Sacchettini; Thomas R Ioerger; Eric J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

5.  Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors:  Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

6.  Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.

Authors:  Gopinath Viswanathan; Sangya Yadav; Tirumalai R Raghunand
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams To Inhibit Mycobacterial Growth.

Authors:  Nathan Wlodarchak; Nathan Teachout; Jeffrey Beczkiewicz; Rebecca Procknow; Adam J Schaenzer; Kenneth Satyshur; Martin Pavelka; William Zuercher; David Drewry; John-Demian Sauer; Rob Striker
Journal:  Mol Pharm       Date:  2018-10-18       Impact factor: 4.939

8.  The RipA and RipB Peptidoglycan Endopeptidases Are Individually Nonessential to Mycobacterium smegmatis.

Authors:  Daniel J Martinelli; Martin S Pavelka
Journal:  J Bacteriol       Date:  2016-04-14       Impact factor: 3.490

9.  Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors:  Amit Kaushik; Nayani Makkar; Pooja Pandey; Nicole Parrish; Urvashi Singh; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

Review 10.  β-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis.

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.